Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response

Hepato-Gastroenterology

Volumn 45, Issue 19, 1998, Pages 133-136

  Yamakawa, Yohsuke ^a   Sata, Michio ^a   Suzuki, Hiroshi ^a   Tanaka, Kumi ^a   Tanaka, Eisuke ^a   Noguchi, Seiji ^a   Ono, Katsuyuki ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Genotype; HCV RNA; IFN

Indexed keywords

INTERFERON; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031937314     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hoft U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke HA, Walter E, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10:69-76.
2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-5.
3. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogencsis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18:47-53.
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HJ, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-6.
5. Di BA, Martin P, Kassianides C, Lisker MM, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
6. Shindo M, Di BA, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15:1013-6.
7. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interleron [letter]. Lancet 1992; 339.
8. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C [published erratum appears in Lancet 1993 Aug 21; 342(8869):504] [see comments]. Lancet 1993; 341:1501-4.
9. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon α therapy, Gastroenterology 1993; 104:877-83.
10. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994; 42:299-305.
11. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39:977-82.
12. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-94.
13. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, Hayashi K, et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favourable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46:109-15.
14. Yoshioka A, Higashi Y, Yamada M, Aiyama T, Takayanagi M, Tanaka A, Okumura A, et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver 1995; 15:57-62.
15. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K, Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39:1273-80.
16. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-9.
17. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74:661-8.
18. Kato N, Yokosuka O, Hosuda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18:16-20.
19. Kaneko S, Murakami S, Unoura M, Kobayashi K. Quantitation of hepatitis C virus RNA by competitive polymerase chain reaction. J Med Virol 1992; 37:278-82.
20. Marlinot PM, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, Wild AM, et al. Detection and quantitation of serum HGV-RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994; 20:676-8.
21. Hino A, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 1995; 40:14-20.
22. Chayama K, Kobayashi M, Tsubota A, Koida I, Arase Y, Saitoh S, Ikeda K, et al. Molecular analysis of intraspousal transmission of hepatitis G virus. J Hepatol 1995; 22:431-9.
23. Saitoh H, Naitoh S, Okamoto H, Akahane Y. Prompt decrease of circulating hepatitis G. virus in patients with chronic hepatitis G after treatment with interferon J Interferon Res 1994; 14:239-44.